Results 81 to 90 of about 9,672 (236)

Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir

Journal of Pharmaceutical Health Care and Sciences, 2020
Background Interferon and ribavirin have been used as therapeutic agents for chronic hepatitis C infection or C-compensated cirrhosis in the conventional treatment.
Sachiko Omotani, Toshihiko Ishizaka, Miki Inoue, Koji Nishida, Yukako Yasui, Yasutoshi Hatsuda, Junji Mukai, Michiaki Myotoku   +7 more
doaj   +1 more source

Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents [PDF]

, 2016
Association between HCV infection and diabetes has been widely postulated. Little is known about the impact of direct acting antiviral agents (DAAs) on glycemic control. Aim of our study was to evaluate the glycemic control modifications in a case series
D'Ettorre, G., LICHTNER, Miriam, MAROCCO, RAFFAELLA, MASTROIANNI, Claudio Maria, MEZZAROMA, Ivano, Passavanti, G., pavone, paolo, TIEGHI, TIZIANA, VITTOZZI, PIETRO, VULLO, Vincenzo   +9 more
core   +1 more source

Clearance of Hepatitis C Viremia During Direct‐Acting Antiviral Therapy Leads to Rapid Changes in Lipid and Lipoprotein Metabolism

Alimentary Pharmacology &Therapeutics, Volume 62, Issue 2, Page 146-158, July 2025.
HCV clearance during direct‐acting antiviral therapy rapidly increases serum lipids and lipoproteins, potentially elevating cardiovascular risk. These metabolic changes, mediated by genes regulating hepatic lipogenesis, suggest that lipid levels should be closely monitored post‐SVR to assess long‐term cardiovascular implications.
Zahra Sarrafan‐Chaharsoughi, Varun Takyar, Sungyoung Auh, Gavin Nee, Ahmad Alawad, Brent S. Abel, Devika Kapuria, Colleen Byrnes, Anna Wolska, David E. Kleiner, Robert Shamburek, Alan T. Remaley, Marc G. Ghany   +12 more
wiley   +1 more source

Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective

Therapeutics and Clinical Risk Management, 2016
Marcel Nkuize,1 Thomas Sersté,1,2 Michel Buset,1 Jean-Pierre Mulkay11Department of Gastroenterology and Hepatology, Saint-Pierre University Hospital, 2Department of Gastroenterology, Pancreatology and Hepatology, Hôpital Academique Erasme ...
Nkuize M, Sersté T, Buset M, Mulkay JP
doaj  

Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir

Hepatology Communications, 2018
Ledipasvir‐sofosbuvir, a once‐a‐day, oral combination pill, was approved in 2014 for the treatment of chronic hepatitis C infection. Initial trials did not comment on nephrotoxicity; however, recent data suggest a risk of acute kidney injury (AKI) with ...
Patrick R. Brown, Omar Sadiq, Alexander Weick, Adrienne Lenhart, Mohammad Elbatta, Christopher Fernandez, Anas Kutait, Robert Pompa, Syed‐Mohammed Jafri   +8 more
doaj   +1 more source

Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study

BMC Gastroenterology, 2020
Background We investigated real-world effectiveness and safety of sofosbuvir and the nonstructural protein 5A inhibitors in the treatment of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, 4, or 6.
Phunchai Charatcharoenwitthaya, Virasak Wongpaitoon, Piyawat Komolmit, Wattana Sukeepaisarnjaroen, Pisit Tangkijvanich, Teerha Piratvisuth, Theeranun Sanpajit, Chinnavat Sutthivana, Chalermrat Bunchorntavakul, Abhasnee Sobhonslidsuk, Soonthorn Chonprasertsuk, Chotipong Siripipattanamongkol, Supatsri Sethasine, Tawesak Tanwandee, The THASL Collaborating Group for the Study of the Use of Direct-acting Antivirals for Chronic Hepatitis C   +14 more
doaj   +1 more source

Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies [PDF]

, 2018
[Abstract] The presence of resistance‐associated substitutions (RASs) at NS5A region might compromise the efficacy of Direct Acting Antiviral agents (DAAs).
Bagaglio, Black, Calleja, Chen, Dietz, Foster, Kalaghatgi, Lindström, Nelson, Palladino, Paolucci, Pawlotsky, Plaza, Poveda, Poveda, Pérez, Sarrazin, Wyles, Zeuzem, Zeuzem, Zeuzem   +20 more
core   +2 more sources

Changes in serum myostatin levels among patients with type C liver cirrhosis treated with direct‐acting antivirals

Hepatology Research, Volume 55, Issue 5, Page 631-637, May 2025.
Direct‐acting antiviral treatment for patients with type C liver cirrhosis not only improves the liver function, but also reduces the myostatin level, which is associated with muscle atrophy. Therefore, antiviral therapy may improve sarcopenia associated with chronic liver disease.
Tomoyuki Suehiro, Hideko Kozuru, Kosuke Matusmoto, Yuki Kugiyama, Yasuhide Motoyoshi, Akira Saeki, Shinya Nagaoka, Kazumi Yamasaki, Atsumasa Komori, Hiroshi Yatsuhashi   +9 more
wiley   +1 more source

Direct‐Acting Antiviral Treatment Failure and Retreatment Strategies Following Hepatitis C‐Positive Solid Organ Transplantation in Hepatitis C‐Negative Recipients: A Multicenter Case Series

Transplant Infectious Disease, Volume 27, Issue 3, May/June 2025.
A multicenter, retrospective case series describes the population of hepatitis C virus (HCV) donor+/ recipient− (D+/R−) solid organ transplant (SOT) recipients failing an initial direct‐acting antiviral (DAA). Retreatment strategies and subsequent sustained virologic response (SVR) rates are reported.
Alicia B. Carver, Claire Özoral, Morgan Lange, Alysa Mattise, Kristen Whelchel, Roman Perri   +5 more
wiley   +1 more source

Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service

ClinicoEconomics and Outcomes Research, 2017
Kirsten Y Westerhout,1 Walter Bouwmeester,1 Inge Duchesne,2 Marta Pisini,2 Marjanne A Piena,1 Francesco Damele,3 Beatrice Gueron,2 Maarten Treur,1 Jonathan Belsey4 1Pharmerit BV, Marten Meesweg, Rotterdam, the Netherlands; 2Janssen EMEA, Turnhoutseweg ...
Westerhout KY, Bouwmeester W, Duchesne I, Pisini M, Piena MA, Damele F, Gueron B, Treur M, Belsey J   +8 more
doaj